Literature DB >> 9220390

An evaluation of nine commercial EIA kits for the detection of measles specific IgG.

L Hesketh1, A Charlett, P Farrington, E Miller, T Forsey, P Morgan-Capner.   

Abstract

Nine commercial EIAs for measles-specific IgG were compared with haemagglutination inhibition (HI) and plaque reduction neutralization (PRN). A total of 174 sera selected, to give approximately half of the sera without measles antibody by HI, were tested by all EIAs and HI. However, there was sufficient volume of only 101 samples for testing by PRN. A dilution curve of the British Standard measles antibody serum was also tested by each EIA. Assays were evaluated qualitatively against a consensus EIA result, HI and PRN: Gull, Melotest and Behring EIAs performed best. Quantitative evaluation was by assessment of the characteristics of the standard dilution curve, and by plotting differences with PRN against mean: Gull and Melotest EIAs were best.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9220390     DOI： 10.1016/s0166-0934(97)02210-6

Source DB:  PubMed          Journal:  J Virol Methods        ISSN： 0166-0934            Impact factor:   2.014


  10 in total

1.  Immunity to measles in the Croatian population.

Authors:  Berislav Borcić; Renata Mazuran; Bernard Kaić
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

2.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

3.  Potential application of nonstructural protein NS1 serotype-specific immunoglobulin G enzyme-linked immunosorbent assay in the seroepidemiologic study of dengue virus infection: correlation of results with those of the plaque reduction neutralization test.

Authors:  Pei-Yun Shu; Li-Kuang Chen; Shu-Fen Chang; Yi-Yun Yueh; Ling Chow; Li-Jung Chien; Chuan Chin; Hui-Hua Yang; Ting-Hsiang Lin; Jyh-Hsiung Huang
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

5.  Comparison of the neutralizing and ELISA antibody titres to measles virus in human sera and in gamma globulin preparations.

Authors:  Holger F Rabenau; Branko Marianov; Sabine Wicker; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-17       Impact factor: 3.402

6.  Evaluation of six immunoassays for detection of dengue virus-specific immunoglobulin M and G antibodies.

Authors:  J Groen; P Koraka; J Velzing; C Copra; A D Osterhaus
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

7.  Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models.

Authors:  E O Ohuma; E A Okiro; A Bett; J Abwao; S Were; D Samuel; A Vyse; N Gay; D W G Brown; D J Nokes
Journal:  Epidemiol Infect       Date:  2008-06-10       Impact factor: 2.451

8.  Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Clin Vaccine Immunol       Date:  2008-05-07

9.  Estimating seroprevalence of vaccine-preventable infections: is it worth standardizing the serological outcomes to adjust for different assays and laboratories?

Authors:  G Kafatos; N Andrews; K J McConway; C Anastassopoulou; C Barbara; F De Ory; K Johansen; J Mossong; K Prosenc; R Vranckx; A Nardone; R Pebody; P Farrington
Journal:  Epidemiol Infect       Date:  2014-11-25       Impact factor: 4.434

10.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.